Mary L. Disis

1 month ago | digitalcommons.library.tmc.edu | Mary L. Disis

AbstractAdvanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors.

2 months ago | jamanetwork.com | Mary L. Disis

Ten years ago, when we started JAMA Oncology, our goal was to create a journal that would be “one-stop shopping” for oncology clinical science. Our scope was to publish scientific discoveries and innovations that would have either immediate importance to the reader or have the potential to be practice changing within the next 5 years. Our north star was, and still is, science that impacts patient care.

Mar 20, 2025 | jamanetwork.com | Mary L. Disis

This past year, 2024, brought many exciting practice-changing publications to JAMA Oncology across a wide variety of topics. Throughout the year, we published several randomized clinical trials that changed the course of clinical care1-3 and a substantial number of studies on cancer survivorship.

Mar 20, 2025 | jamanetwork.com | Mary L. Disis

JAMA Oncology Peer Reviewers in 2024 We sincerely thank the 581 peer reviewers who completed manuscript reviews for JAMA Oncology in 2024.

Mar 20, 2025 | jamanetwork.com | Mary L. Disis

This past year, 2024, brought many exciting practice-changing publications to JAMA Oncology across a wide variety of topics. Throughout the year, we published several randomized clinical trials that changed the course of clinical care1-3 and a substantial number of studies on cancer survivorship.